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Background: There is ample evidence that inﬂammatory processes play a role in the pathophysiology of schizo-
phrenia. Randomized controlled trials have shown beneﬁt of some (but not all) anti-inﬂammatory drugs on
symptom severity. So far, these drugs have been given for a relatively short period. Simvastatin combines
well-established vascular protection with reduction of the inﬂammatory status of the brain, thus offering an
attractive potential to further improve treatment of schizophrenia and related disorders.
Methods/design: We are currently undertaking a double-blind placebo-controlled trial, including 250 patients
(18–50 years of age) whom are diagnosedwith a schizophrenia spectrum disorder. Onset of their ﬁrst psychosis
should be no longer than three years ago. Patients are randomized 1:1 to either 40 mg simvastatin or placebo
daily during one year, next to their regular antipsychotic treatment. Primary outcome measures are symptom
severity and cognitive decline as measured by the Positive and Negative Syndrome Scale (PANSS) and Brief
Assessment of Cognition in Schizophrenia (BACS), at baseline and end of treatment. Secondary aims are to estab-
lish an attenuation of brain tissue loss and an improvement in general functioning, presence and severity of
metabolic syndrome and degree of movement disorders. Lastly, immunological and metabolic parameters are
assessed in blood samples to possibly predict treatment response.
Discussion: We hypothesize simvastatin to lower symptom severity and to prevent or reduce excessive brain
tissue loss and cognitive decline, compared to placebo. We expect that simvastatin will be well-tolerated and
lead to decreased prevalence of metabolic syndrome.
Trial registration: ClinicalTrails.gov NCT01999309; EudraCT-number 2013-000834-36.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although the introduction of antipsychotic medications in the 1950s
has substantially improved clinical symptoms of schizophrenia [32], the
disease is still causing considerablemorbidity andmortality [28]. Differ-
ent lines of evidence now suggest that low-grade inﬂammation in the
central nervous system is involved in the pathogenesis of schizophrenia,
possibly affecting a speciﬁc subgroup of patients. These include the
increased risk of schizophrenia patients and their relatives for specif-
ic auto-immune diseases [6], clinical similarities between the course
of schizophrenia and auto-immune disease [23] and decreased prev-
alence of schizophrenia in men who have used non-steroidal anti-
inﬂammatory drugs (NSAIDs) [24] or glucocorticosteroids [25] for
somatic disorders. Furthermore, an infectious cause or trigger ise Division, Heidelberglaan 100,
H. Begemann).
. This is an open access article undersuggested by the observed association between schizophrenia and
pre- and perinatal infections [10], as well as by seroconversion to
certain pathogens in patients with schizophrenia [33].
The case of this increased inﬂammation is most likely both genetic
and environmental. A large pooled data-set of single nucleotide poly-
morphism (SNP)-based genome-wide association studies followed up
themost signiﬁcant association signals [31]. Oneof themost remarkable
ﬁndingswas a signiﬁcant associationwith severalmarkers spanning the
major histocompatibility complex (MHC) region on chromosome
6p21.3–22.1. This genetic deviation in the MHC region is consistent
with an immune component to schizophrenia risk. Furthermore, recent
studies suggest that negative environmental inﬂuences such as child-
hood trauma and drug abuse affect the brain by increasing the inﬂam-
matory response [1,7].
On a cellular level, inﬂammation of the central nervous system is
suggested by an increased number of activated microglia cells in the
brains of patients with recent-onset psychoses as visualized by positron
electron tomography [14,34]. In an activated state, microglia cells canthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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toxic substances, causing cell death in their proximity [27], while at
rest microglia are an important source of growth factors. The activation
of microglia cells provides a possible route by which an increased pro-
inﬂammatory state in the brain could cause increased grey matter loss
and more severe negative and cognitive symptoms.
In support of this line of thought, cross-sectional studies showed a
negative correlation between an inﬂammatory parameter in the blood
(C-reactive protein; CRP) and cognitive performance in people with
schizophrenia [12,13]. CRP and other inﬂammatory markers (including
S100B, interleukin [IL]-6 and IL-8) have also been associatedwith severity
of negative symptoms [26]. Furthermore, MRI studies showed larger
cerebral volume decreases in poor outcome patients, characterized by
more symptoms and lower levels of daily life functioning [35,36]. This
more pronounced brain volume loss occurs mainly in the ﬁrst years of
illness [4,8] and may be related to increased inﬂammatory status in the
brain. A recentmeta-analysis [38] including 26 double-blind randomized
controlled trials evaluated the efﬁcacy of anti-inﬂammatory agents,
showing promising results. Aspirin additionwas found to have beneﬁcial
effects (meanweighted effect size [ES]: 0.3,n=270), aswell as estrogens
(ES: 0.51, n= 262), and N-acetylcysteine (ES: 0.45, n= 140).
This mounting body of evidence suggests that anti-inﬂammatory
drugs can be viewed as potential candidates for new augmentation ther-
apies, although at this stage it is unknown if increased pro-inﬂammatory
status is characteristic for all patients with schizophrenia or just for a
speciﬁc subset of them. A recent post-mortem study showed clear signs
of increased inﬂammation in some 40% of patients [15], which parallels
ﬁndings in peripheral blood also showing increased inﬂammation in
35% of patients [29]. Thus, augmentation with an anti-inﬂammatory
component may be particularly beneﬁcial for this subgroup.
Sierra et al. [30] compared nine statins for their potential as a neuro-
protective agent and concluded that simvastatin is the best candidate
for the prevention of neurodegenerative conditions due to its high
capacity to penetrate the blood–brain-barrier, strong cholesterol lower-
ing effect on neurons and (in vitro) protection against neural cell death.
However, statins have anti-inﬂammatory effects that are independent
of their ability to lower cholesterol. Individuals with schizophrenia
already have high levels of cardiovascular risk factors [18]. Statin treat-
ment that combines anti-inﬂammatory with cardioprotective proper-
ties may therefore have particular potential as adjuvant therapy in
patients with recent-onset schizophrenia.
1.1. Aims
We hypothesize that simvastatin addition will have a beneﬁcial
effect in patients with early-stage psychotic disorder on the following
outcome variables:
• Primary: Symptom severity and cognitive performance;
• Secondary: Brain volume loss, global functioning, movement disor-
ders, and metabolic and inﬂammatory parameters.
2. Methods
2.1. Overview
This is a randomized, double-blind, placebo-controlled study of sim-
vastatin addition 40mg/day for patients with recent-onset psychosis. A
placebo-controlled design was chosen in order to differentiate between
clinical effects of simvastatin and effects associated with experimental
treatment, such as induced expectations of participants. Randomization
is applied to minimize bias. A total of 250 patients with a DSM-IV diag-
nosis of schizophrenia, schizoaffective or schizophreniform disorder, or
psychotic disorder NOS (not otherwise speciﬁed) will be included in a
period of three years, between 18 and 50 years of age and onset ofﬁrst psychosis no longer than three years ago. Multiple psychosis-
related diagnoses are allowed within this study, as recent scientiﬁc
developments substantiate that these diagnoses share an underlying
pathophysiology. This scientiﬁc development is illustrated by the edito-
rial comment by NIMH director Thomas Insel (http://www.nimh.nih.
gov/about/director/2013/transforming-diagnosis.shtml).
Patients will be recruited from both inpatient and outpatient
settings throughout the Netherlands. The patients will be identiﬁed
and ﬁrst approached by their treating psychiatrist and the multi-
disciplinary teams. When patients are eligible to participate after the
screening procedure, theywill be randomized to simvastatin or placebo.
Clinical and cognitive assessment will be done during the baseline visit,
in addition to an MRI scan, after which the patient will start with the
studymedication. Patients will continue with their antipsychotic medi-
cation as usual during the trial. Study assessments will be conducted by
members of the study team, while the treating psychiatrist will remain
in charge of the overall treatment. Any changes in type or dosage of
antipsychotic medication will be recorded on each study visit. During
the course of the study the patient will also have additional support
from the study team and continued support from their mental health
care team.
2.2. Allocation
All 250 patients will be randomized 1:1 to either 40 mg simvastatin
or placebo daily, with a treatment period of 12monthswhile continuing
their antipsychoticmedication as prescribed by their treating physician.
A web-based application will be used, and stratiﬁcation will be applied
for center and gender. Trial treatment randomization codes will not be
available to the study staff, but will be conveyed to the pharmacy in
the University Medical Centre Utrecht in case emergency deblinding is
needed. Emergency unblinding is only allowed in case of serious con-
cerns about patient safety.
2.3. Inclusion criteria
1. A DSM-IV-R diagnosis of: 295.x (schizophrenia, schizophreniform
disorder, or schizoaffective disorder) or 298.9 (psychosis NOS)
2. Onset of ﬁrst psychosis no longer than 3 years ago
3. Age between 18 and 50 years
4. Written informed consent is obtained.
5. Female patients of childbearing potential need to utilize a proper
method of contraception.
2.4. Exclusion criteria
1. Fulﬁllment of criteria for statin prescription; according to the
Dutch Heart Foundation (Hartstichting), statin treatment is in-
dicated when the total cholesterol level is N8 mmol/l (www.
hartstichting.nl);
2. Presence of any of the contra-indications or warnings for the use
of simvastatin as reported in the SPC;
3. Chronic use of glucocorticosteroids (temporary use is permit-
ted, if stopped at least 1 month before start of treatment trial);
4. Chronic use of non-steroidal anti-inﬂammatory drugs (tempo-
rary use is permitted, if stopped at least 1 month before start
of treatment trial);
5. Current use of statins or other lipid-lowering drugs;
6. Pregnancy or breast-feeding (urine pregnancy test will be per-
formed for sexually active females with child bearing potential);
7. In case of familial risk for muscular disorders or previously
experienced muscle toxicity when taking medication similar to
simvastatin, creatine kinase (CK) levels will also be checked
(as recommended by the Dutch Farmacotherapeutisch Kompas,
www.farmacotherapeutischkompas.nl). In addition, levels of
aspartate aminotransferase (ASAT), alanine aminotransferase
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will be checked when a history of alcohol abuse, liver or kidney
disorders is reported;
8. Use of comedication that either inhibits or induces the live enzyme
CYP3A4,which is responsible for thedegradationof simvastatin. Inhib-
itors of CYP3A4 include itraconazole, ketoconazole, posaconazole,
ﬂuconazole, erythromycin, clarithromycin, telithromycin, HIV prote-
ase inhibitors, nefazodone, telaprevir, boceprevir, imatinib, ticagrelor,
and voriconazole; inducers of CYP3A4 include carbamazepine,
efavirenz, nevirapin, and etravirine (can be washed out before
start of trial);
9. Use of comedication thatmay increase the risk formyalgia, rhabdomy-
olysis andmyopathy, including colchicine, bosentan, fenobarbital, phe-
nytoin, hypericum, rifabutin, rifampicin, ﬁbrates (e.g. gemﬁbrozil),
fusidic acid, and carbamazepine (can be washed out before start of
trial).
For patients, theMRI scan requires additional exclusion criteria to be
eligible to participate in this part of the study (if these additional criteria
are not met, patients can participate in the study but not in the MRI
component):
10. Ferrous objects in or around the body (e.g. braces, glasses, pacemak-
er, metal fragments);
11. Claustrophobia.
2.5. Interval assessments
A total of 8 visits will be conducted throughout a period of one year
(see Table 1). During the screening visit, informed consent will be
signed and in- and exclusion criteria will be checked. If the patient is
eligible for participation, the patient will be randomized. An experi-
enced researcher will interview the patients at each visit using the
PANSS questionnaires. Furthermore, side effectswill be checked, assess-
ment of GAF score and studymedication countwill be conducted during
each visit. Cognitive testing and MRI scanning will take place at the
baseline visit and at the end of the experimental treatment after one
year. With regard to metabolic and immunological measurements,
blood will be drawn at the baseline visit, after 1, 6 and 12 months and
at follow-up (24months) in addition tomeasurements of waist circum-
ference, body mass index (BMI) and blood pressure. Patients are exam-
ined for movement disorders at baseline, 6 months and 12months, and
the questionnaire on childhood trauma will be ﬁlled in at baseline.Table 1
Schedule of assessments.
Assessment Visit 1
screening
Visit 2
(baseline)
Check-up
(2 weeks, call)
Visit 3
(1 month)
Vis
(3 m
In- and exclusion criteria x
Consent x
Lab screening x
Drug treatment history x x x
Withdrawal criteria x x
CASH x
PANSS x x x
Cognitive assessment x
MRI scan x
GAF x x x
Physical examination x x
Movement disorders x
Blood samples x x
CTQ-SF x
CDSS x
Drug/alcohol use x
Side effects simvastatin x x x
Compliance monitoring x x
Abbreviations: CASH = Comprehensive Assessment of Symptoms and History; PANSS = Posi
Assessment of Functioning; CTQ-SF = Childhood Trauma Questionnaire—Short Form; CDSS =2.6. Training and inter-rater reliability
All involved researchers will be trained in the PANSS interview by
using instructional videos and group-wise assessment of a test video.
Researchers have to pass an exam before he/she can perform PANSS
ratings for this study. Proper conduct of the CASH interview, movement
disorders scales, and cognitive testing will also be trained by experts.
Study members will be carefully selected and comprehensively in-
formed and trained regarding Good Clinical Practice (GCP).2.7. Treatment
During the study, all patients will continue their antipsychotic
medication as prescribed by their treating physician. The study medica-
tion will be ingested in the evening at a ﬁxed dosage of 40 mg, which is
within the registered dose range of 5–80 mg/daily. Patients will ingest
the study medication in the form of identical tablets (e.g. simvastatin
and placebo). No dosage modiﬁcations will take place.2.8. Outcome variables
2.8.1. Primary outcome variables
2.8.1.1. Clinical outcome measure. Symptom severity will be evaluated
using the Positive and Negative Syndrome Scale (PANSS [total score];
[21]). We expect to ﬁnd lower symptom severity as measured with
the Positive and Negative Symptom Scale (PANSS) with an average of
at least 7.5 points compared to baseline, over the course of one year.2.8.1.2. Cognitive outcome measures. Neurocognitive functioning will be
assessed with the Brief Assessment of Cognition in Schizophrenia
(BACS; [22]), including the following tests:
1. Verbal memory: List Learning
2. Working memory: Digit Sequencing Task
3. Motor speed: Token Motor Task
4. Verbal ﬂuency: Category Instances
5. Verbal ﬂuency: Controlled Oral Word Association Test
6. Attention and speed of information processing: Symbol Coding
7. Executive functions: Tower of Londonit 4
onths)
Visit 5
(6 months)
Visit 6
(9 months)
Visit 7
(12 months)
Early
termination
Follow-up
(24 months)
x x x x x
x x x x
x x x x x
x x x
x x
x x x x x
x x x x
x x x x
x x x x
x x x x
x x x
x x x x
x x x x
tive and Negative Symptoms Scales; MRI = Magnetic Resonance Imaging; GAF = Global
Calgary Depression Scale for Schizophrenia.
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2.8.2.1. Magnetic Resonance Imaging outcome measures. Changes in
brain abnormalities and brain tissue loss will be investigated by
means of Magnetic Resonance Imaging (MRI). Speciﬁcally, we will
measure changes in: 1) global grey matter volumes cerebral, corti-
cal and ventricle areas as measured with MRI; 2) widespread white
matter integrity changes throughout the frontal, temporal, parietal
and occipital lobes as measured with Diffusion Tensor Imaging
(DTI) and Magnetic Transfer Ratio (MTR) scans; 3) quantitative
MRI by using mcDESPOT scans which will provide an additional
higher spatial resolution scan to investigate the global effects of
simvastatin on the brain. We will compare the effect of simvastatin
versus placebo, both given in addition to antipsychotic medication,
with regard to changes in the primary outcome variables alluded
above.
2.8.2.2. Clinical outcome measures. Secondary study parameters are the
PANSS subscales: the positive scale, negative scale and general psy-
chopathology scale. General functioning will be evaluated using the
Global Assessment of Functioning scale (GAF; [19]), and the pres-
ence and severity of metabolic syndrome will be assessed as deﬁned
by the American Heart Association/National Heart, Lung and Blood
Institute (AHA/NHLB; [17]), by measuring weight, height, blood
pressure, waist circumference, and bodymass index (BMI). The pres-
ence and severity of movement disorders will be evaluated using St.
Hans Rating Scale (SHRS; [16]) and the Barnes Akathisia Rating Scale
(BARS; [5]).
2.8.3. Other objectives
Various immunological andmetabolic parameterswill be assessed in
blood samples to examine whether these parameters predict treatment
response to simvastatin augmentation. Therefore, serum, peripheral
blood mononuclear cells (PBMC) and RNA will be collected. The follow-
ing markers will be investigated: triglycerides, HDL-C, fasting glucose,
cholesterol, LDL and CRP. In addition, experience of childhood trauma
will be assessed using the Childhood Trauma Questionnaire—Short
Form (CTQ-SF; [9]). The severity of depression will be evaluated using
the Calgary Depression Scale for Schizophrenia (CDSS; [2]). Finally, safe-
ty data will be evaluated by comparing incidences (number and % of
subjects with at least one occurrence) of key SAEs and SUSARs between
both groups (e.g. hospitalisations).
2.9. Safety assessment
2.9.1. Medical history
Medical history and current medication use will be checked at
each visit to assess in- and exclusion criteria with regard to contrain-
dications. Blood will be screened for cholesterol in order to conclude
whether a patient can participate or whether statin treatment for
high cholesterol (N8 mmol/L) needs to be part of the regular medical
treatment.
2.9.2. Physical and blood examinations
In case a patient reports side effects of simvastatin use, physical
examination will be conducted and blood will be drawn to conclude
whether participation needs to be terminated.
2.9.3. Adverse events (AE)
Adverse events are deﬁned as any undesirable experience occurring
to a subject during the study, whether or not considered related to the
investigational product. All adverse events reported by the subject or
observed by the investigator or his staff will be recorded. During each
visit, side effects or healthy issues will be checked. The patient will be
asked by an open question if he experienced any side effects or healthy
problems since the last visit, moreover it will be explicitly asked if thepatient experienced unexplainedmuscle pain or dark urine, as these in-
clude the most common side effects of simvastatin. Serious adverse
events (SAEs) will be reported according to the protocol and recorded
in the case report form.2.10. Power calculation and statistical analysis
An expected difference between groups of at least 7.5 points on
the Positive and Negative Syndrome Scale (PANSS) questionnaire is
considered relevant. In order to be able to detect this difference,
113 participants in each group will have to be evaluated to have
80% power at a two-sided alpha of 5%. The expected standard devia-
tion of the total PANSS score used for this sample size calculation is
based on similar data of the Eufest trial [20] and set to 20. This sam-
ple size calculation assumes the primary analysis will be a t-test
comparing the two treatment groups on mean change from baseline
to 12 months of treatment. However, the primary analysis will actu-
ally be based on a linear model including at least treatment arm and
baseline PANSS score as covariates. If the correlation between base-
line PANSS and PANSS at 12 months follow-up is 0.4 or higher,
which is not unreasonable, the statistical evaluation is approximate-
ly at least (0.4)2 more efﬁcient, in that 16% less patients are required.
This greater efﬁciency can partly compensate for the anticipated
drop-out, which is expected to be between 20 and 30% given the
relative long duration of the study. It is thus expected that 125
patients in each arm will sufﬁce, resulting in a total of 250 partici-
pants in this study.
Intention To Treat analyses will be conducted. Descriptive statis-
tics of continuous outcomes will be presented by treatment arm and
include sample size, mean, median, standard deviation, minimum
and maximum. For categorical outcomes, the number and percent-
age of subjects in each category will be presented by treatment
arm. All statistical analyses will be performed using SPSS for Win-
dows (version 20) or other widely accepted statistical or graphical
software. The primary analysis will include PANSS scores at 1, 3, 6,
9 and 12 months follow-up in a repeated measurements model.
The model will be a mixed model for repeated measurements
including at least time point, treatment group, the interaction
between time point and treatment, sex, age and severity as ﬁxed
factors, baseline PANSS score as covariate and subject as random
intercept factor. An cAR(1) structure will be used tomodel the resid-
ual covariance matrix. The primary analysis will be to test the
contrast between simvastatin addition and control at 12 months of
treatment. This will be presented with a 95% conﬁdence interval
for the difference between the treatment arms. In addition, post-
hoc analyses will be conducted to investigate possible differences
at individual time points. The analyses on neurocognitive functioning
will be similar, although only scores after 12 months of treatment are
included. The BACS total composite score will be evaluated, as well
as post-hoc analyses to evaluate the six individual subtasks (as sug-
gested by [22]). The raw test scores of the subtasks will be converted
into z-scores The total composite score will be calculated by averag-
ing the standardized scores from the individuals subtests of the
BACS. The secondary analyses on continuous measures (including
the PANSS positive, negative and general psychopathology scales,
in addition to MRI data) will be similar to the primary analyses
(but note that the number of time points is different here). Second-
ary analyses on dichotomous data (e.g. on presence of metabolic syn-
drome and movement disorders) will be conducted using logistic
regression analysis. The analyses on other study parameters, includ-
ing data from the 24-month follow-up visit, on continuous and
dichotomous measures will also be similar to the primary and
secondary analyses (but again with a different number of time
points). For safety data, incidences (number and % of subjects
with at least one occurrence) of key SAEs and AEs will be presented
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ing both groups will be provided.
2.11. Study procedures
2.11.1. Recruitment
Patients diagnosed with schizophrenia, schizoaffective or
schizophreniform disorder (DSM-IV 295.*) or psychosis NOS
(298.9) will be invited to participate by their treating physician.
Psychiatrists associated in the Dutch Psychosis Consortium collab-
orate on several treatment trials, including this one.
2.11.2. Screening visit
Participation in the study is preceded by an informative meeting
with the study investigator, during which the participant must be
informed about the entire course of the study, potential individual
beneﬁts and personal risks. Here it must be emphasized that partic-
ipation is absolutely voluntary. Patients are given sufﬁcient time to
read all the provided information, counsel partners or relatives,
and clarify any questions with the investigator. Participation re-
quires written consent before any (screening) procedure takes
place. This consent can be revoked at any time without citing rea-
sons and without any consequences. A copy of the consent form
and patient information will be given to the participant. After the
informed consent procedure has been completed, in- and exclusion
criteria will be checked to assess the patient's eligibility for partic-
ipation. In case of familial risk for muscular disorders or previously
experienced muscle toxicity when taking medication similar to
simvastatin, creatine kinase (CK) levels will also be checked. In
addition, levels of aspartate aminotransferase (ASAT), alanine ami-
notransferase (ALAT), gamma-glutamyltranspeptidase (γ-GT) and
creatinine will be checked when a history of alcohol abuse, liver or
kidney disorders, is reported. In addition, total cholesterol level will
be measured to determine whether the reference level of 8 mmol/l is
exceeded, in which case the patient cannot be included in the study
and is referred to the general physician as statin use is indicated
(www.hartstichting.nl). These results will be evaluated by a physi-
cian before the baseline visit takes place.
The Comprehensive Assessment of Symptoms and History (CASH) [3]
will be administered to conﬁrm the inclusion diagnosis. In addition,
several demographical and clinical variables will be assessedwith this in-
strument, including date of birth, sex, educational level, prior psychiatric
disorders and duration of untreated psychosis. Furthermore, the use of
concomitant medication, medical history and current medical condi-
tions/adverse events will be recorded.
2.11.3. Baseline visit
At baseline, the patientwill be randomised and the studymedication
will be dispensed for the ﬁrst time at the end of the visit, see Table 1.
PANSS and GAF will be administered, in addition to the CDSS and the
BACS. With regard to metabolic and immunological measurements,
the blood will be drawn at the baseline visit, in addition to measure-
ment of waist circumference, body mass index and blood pressure.
Patients are examined for movement disorders, namely tardive dyski-
nesia, parkinsonism, akathisia and tardive dystonia, using a standard
protocol, described by van Harten and colleagues [37]. Childhood trau-
ma will be evaluated by asking subjects to ﬁll-in a retrospective self-
report questionnaire (CTQ-SF). In addition, an MRI scan will be per-
formed. At the end of the baseline visit, study medication will be
dispensed and patients are instructed on how to use it. As a ﬁnal
check, no current use of contraindicated comedications is ascertained
again. A study participation letter will be sent to the treating psychia-
trist, general practitioner and pharmacy of the patient, mentioning
these contraindicated comedications. Patients are instructed to contact
the study center if muscle pain, weakness, cramps, or dark urineoccur. Lab procedures that will follow such a report are described in
the section ‘Patient withdrawal’ below.
2.11.4. Treatment visits
After the screening and baseline visits, visits will be conducted at 1,
3, 6 and 9 months and at the end (12 months) of treatment, during
which an experienced researcher will interview patients using the
PANSS and the GAF questionnaires (see Table 1). Cognitive testing and
brain volume assessments will again take place at the end (12 months)
of the study. Depression scores (CDSS) will be assessed at 6 and 12
months. Bloodwill be drawn after 1, 6 and 12months of the experimen-
tal treatment, in addition to measurements of waist circumference,
body mass index and blood pressure. Patients are examined for move-
ment disorders at 6 and 12 months after baseline. During each visit,
the occurrence of side effects will be checked, in addition to use of con-
traindicated co-medications. In case of drop-out, an early termination
visit similar to the end of treatment visit will be performed to ﬁnalize
participation. If the patient is not willing to complete all measures,
priority will be given to the PANSS.
2.11.5. Follow-up visit
A follow-up visit will take place 24 months after baseline in
order to examine any long-term effects of simvastatin on the clin-
ical status of participants as well as immune parameters (see
Table 1). The PANSS and the GAF questionnaires will be adminis-
tered. Cognitive functioning and depressive symptoms will be
assessed, in addition to measurements of waist circumference,
body mass index and blood pressure. Blood will be drawn and pa-
tients are examined for movement disorders. Medication use will
be evaluated, next to side effects and hospitalisation in the past
year.
2.11.6. Patient safety
The patients' day-to-day care is the responsibility of the treating
physician. The safety proﬁle of simvastatin is satisfactory, especial-
ly in a population of recent-onset patients, where the multiple
interactions with other medications will be less often an issue
due to the good somatic health status of such a relatively young
population. Medical and safety concerns speciﬁcally related to par-
ticipation in the study are the responsibility of the principal inves-
tigator (P.I.). The principal investigator and study members can at
all times be contacted at the telephone number provided on the
appointment card and letters patients receive during the study.
2.11.7. Patient withdrawal
Subjects can leave the study at any time for any reason if they wish
to do so, without any consequences. The investigator can decide to
withdraw a subject from the study for urgent medical reasons. Reasons
to terminate a patient's participation include:
• The patient withdraws her/his consent
• Intolerance to the study drug: if a patient experiences unaccept-
able side effects, the patient may decide, or make a joint decision
with the treating physician, to terminate study participation.
• The patient develops myopathy with increased creatine kinase
(CK) levels.
When unexplained muscle pain, weakness, cramps or dark urine
occur, CK, CPK (creatine phosphokinase) and CRP (C-reactive
protein) levels should be measured. If these levels are found to
be signiﬁcantly elevated (N10 × ULN, in the absence of strenuous
exercise) or if pain does not subside with paracetamol use, treat-
ment will be stopped.
• Use of glucocorticosteroids, non-steroidal anti-inﬂammatory
drugs, statins or other lipid-lowering drugs
• Use of comedication that either inhibits or induces the live
enzyme CYP3A4 (responsible for the degradation of simvastatin)
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rhabdomyolysis and myopathy.
In case a patient reports unexplained muscle pain, weakness,
cramps, dark urine, or in case of suspected liver failure or toxicity,
a blood sample will be drawn at the earliest opportunity to assess
levels of CK, CPK (creatine phosphokinase), CRP (C-reactive protein),
aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT),
gamma-glutamyltranspeptidase (γ-GT) and/or creatinine. If these
levels are found to be signiﬁcantly elevated (CK N 10 × ULN, in the ab-
sence of strenuous exercise; ASAT, ALAT or γ-GT N 3 × ULN or in case
of liver damage, hyperbilirubinemia and/or jaundice), or if pain does
not subside with paracetamol use, treatment will be stopped.
• Abnormal level of triglycerides, HDL-C (high-density lipoprotein
cholesterol), fasting glucose, cholesterol, LDL, CRP, which will be
extensivelymonitored. In case of abnormal ﬁndings, the treating phy-
sician and general physician will be contacted. When medical inter-
ventions are needed, the patient will be withdrawn from the study
and will receive medical treatment.
• The nature of the patient's treatment is changed to coercive treatment
(based on judicial ruling)
• Emergence of one ormore contraindications against the study drug as
mentioned in the Summary of Product Characteristics
• Patient becomes pregnant.
• The investigator considers a patient's continued participation in the
study to be unjustiﬁable on medical grounds (i.e., because of side
effects or unusual risks).
If an individual patient is discontinued due to one of the above-
mentioned reasons, this patient will be treated as usual in normal
daily practice. The treating physician remains the primary caregiv-
er during the study and will be contacted at the baseline visit and
updated throughout the study. The treating physician will contact
the study team in cases of important changes and will be responsi-
ble to apply for legal custody if appropriate. All patients leaving the
study early, regardless of the reason, will be requested to return to
the site for an early termination visit to ﬁnalize participation.
2.12. Ethical and regulatory standards
2.12.1. Medical Ethical Review Board
Ethical approval covering all participating sites was obtained
from the research and ethics committee of the University Medical
Center Utrecht (UMCU), the Netherlands, protocol number 13-249.
The trial is registered in the ClinicalTrails.gov database (identiﬁer
NCT01999309) and the European Clinical Trials Database (EudraCT
number 2013-000834-36).
2.12.2. Data and Safety Monitoring Board (DSMB)
It has been decided not to engage Data and Safety Monitoring Board
in this study. The intervention concernsmedication that has been avail-
able on the EU market for two decades. Its safety and efﬁcacy are well-
established. Simvastatin is well-tolerated and if side effects occur, these
are usually minor and require no or minimal treatment. In addition, no
interim analyses are planned. In the investigator's opinion, implementa-
tion of a DSMBwill not have sufﬁcient added value for the current study.
2.12.3. Declaration of Helsinki
This studywill be performed according to theDeclaration of Helsinki
(64th WMA general assembly; October 2013) and the International
Conference on Harmonisation — Good Clinical Practice (ICH-GCP). The
deﬁnitions of adverse events and serious adverse events described in
these guidelines will be used for the present study.3. Discussion
This study will investigate the potential effect of simvastatin to
further improve medical treatment of patients with schizophrenia and
related disorders. A recent medical trial by Chataway and colleagues
[11] demonstrated simvastatin to be effective in reducing annualized
rates of whole brain atrophy in patients with progressive Multiple
Sclerose (MS), which further attributes to simvastatin as a new promis-
ing add-on treatment option for patients with brain diseases that have
an inﬂammatory component. As such, we expect simvastatin to lower
symptom severity, reduce brain tissue loss and cognitive decline when
compared to placebo. Secondly, we expect to ﬁnd increases in the
general functioning using GAF score, reduced presence and severity of
metabolic syndrome and reduced presence and severity of movement
disorders. Lastly, we expect to ﬁnd positive changes in immunological
and metabolic biomarkers related to simvastatin augmentation.
3.1. Trial status
The study is active and currently recruiting patients. We anticipate
completing recruitment by the end of 2016 and ﬁnal assessments
(including follow-up 12 months after study completion) by the end of
2017.
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The Transparency document associated with this article can be
found, in the online version.
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